Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
about
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.Inflammatory genes are novel prognostic biomarkers for colorectal cancer.
P2860
Genomic markers of panitumumab resistance including ERBB2/ HER2 in a phase II study of KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genomic markers of panitumumab ...... atic colorectal cancer (mCRC).
@en
Genomic markers of panitumumab ...... ase II study of KRAS wild-type
@nl
type
label
Genomic markers of panitumumab ...... atic colorectal cancer (mCRC).
@en
Genomic markers of panitumumab ...... ase II study of KRAS wild-type
@nl
prefLabel
Genomic markers of panitumumab ...... atic colorectal cancer (mCRC).
@en
Genomic markers of panitumumab ...... ase II study of KRAS wild-type
@nl
P2093
P2860
P356
P1433
P1476
Genomic markers of panitumumab ...... tatic colorectal cancer (mCRC)
@en
P2093
Garrett S Barry
Hagen F Kennecke
Hector Li Chang
P2860
P304
18953-18964
P356
10.18632/ONCOTARGET.8006
P407
P577
2016-04-01T00:00:00Z